The role of driver mutations in myeloproliferative neoplasms: insights from mouse models
- PMID: 31865539
- DOI: 10.1007/s12185-019-02803-x
The role of driver mutations in myeloproliferative neoplasms: insights from mouse models
Abstract
High frequency of JAK2V617F or CALR exon 9 mutations is a main molecular feature of myeloproliferative neoplasms (MPNs). Analysis of mouse models driven by these mutations suggests that they are a direct cause of MPNs and that the expression levels of the mutated genes define the disease phenotype. The function of MPN-initiating cells has also been elucidated by these mouse models. Such mouse models also play an important role in modeling disease to investigate the effects and action mechanisms of therapeutic drugs, such as JAK2 inhibitors and interferon α, against MPNs. The mutation landscape of hematological tumors has already been clarified by next-generation sequencing technology, and the importance of functional analysis of mutant genes in vivo should increase further in the future.
Keywords: CALR; JAK2; Mouse models; Myeloproliferative neoplasms.
Similar articles
-
[Pathogenesis of myeloproliferative neoplasms: insights from mouse models].Rinsho Ketsueki. 2018;59(10):2075-2083. doi: 10.11406/rinketsu.59.2075. Rinsho Ketsueki. 2018. PMID: 30305511 Review. Japanese.
-
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Ann Hematol. 2017 May;96(5):725-732. doi: 10.1007/s00277-017-2937-6. Epub 2017 Feb 4. Ann Hematol. 2017. PMID: 28161773
-
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Curr Protoc Pharmacol. 2017 Jun 22;77:14.40.1-14.40.19. doi: 10.1002/cpph.23. Curr Protoc Pharmacol. 2017. PMID: 28640953 Free PMC article. Review.
-
Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.Genet Test Mol Biomarkers. 2018 Feb;22(2):98-103. doi: 10.1089/gtmb.2017.0203. Epub 2018 Jan 11. Genet Test Mol Biomarkers. 2018. PMID: 29323541
-
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM. Am J Clin Pathol. 2015. PMID: 25873496
Cited by
-
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Leukemia. 2023 Apr;37(4):843-853. doi: 10.1038/s41375-023-01848-6. Epub 2023 Feb 22. Leukemia. 2023. PMID: 36813992 Free PMC article.
-
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.J Hematol Oncol. 2021 Mar 30;14(1):52. doi: 10.1186/s13045-021-01064-8. J Hematol Oncol. 2021. PMID: 33785036 Free PMC article.
-
Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms.Haematologica. 2021 Jul 1;106(7):1910-1922. doi: 10.3324/haematol.2020.264085. Haematologica. 2021. PMID: 33567809 Free PMC article.
-
Effects of calreticulin mutations on cell transformation and immunity.J Cell Mol Med. 2023 Apr;27(8):1032-1044. doi: 10.1111/jcmm.17713. Epub 2023 Mar 13. J Cell Mol Med. 2023. PMID: 36916035 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous